"Cutting Drug Development Costs" GenomeAndCompany Joins Lilly's AI Platform 'TuneLab'
Predicted impact: Low
Joining Lilly's AI drug platform is a partnership with no disclosed deal size; repeats earlier coverage.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.